Trending: BioNTech Expects Demand Increase in 4Q Despite Lower Earnings
09 August 2022 - 1:04AM
Dow Jones News
BioNTech is among the most-mentioned companies across news items
over the past 12 hours, according to Factiva data, after it said
that it expects its variant-adapted Covid-19 vaccine to boost
demand later in the year. The German biotechnology company reported
lower earnings and revenue for the second quarter but said that it
expects vaccine demand in important markets to pick up in the final
quarter of the year. The shot, which is still pending regulatory
approval, has been adapted for the Omicron variant of Covid-19.
BioNTech reported profit of EUR1.67 billion in the second quarter,
down from EUR2.79 billion the previous year, on revenue which fell
to EUR3.2 billion from EUR5.31 billion in the same quarter a year
prior. Dow Jones & Co. owns
Factiva.(cecilia.butini@wsj.com)
(END) Dow Jones Newswires
August 08, 2022 10:49 ET (14:49 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024